EUVIMEDEUVIMED entdecken
Crossref

Real‐World Impact of Elexacaftor/Tezacaftor/Ivacaftor in Israeli Children Aged 2–6 With Cystic Fibrosis

Adi Dagan iD, Mohamad Hadhud, Ori Efrati, Sharon Sarah Cahanovitc, Dario Prais, Michal Gur iD, Ronen Bar-Yoseph iD, Malena Cohen-Cymberknoh iD

Pediatric Pulmonology · 2026

DOI: 10.1002/ppul.71523 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pediatric Pulmonology, 2026. Verfasst von Adi Dagan und 7 weiteren Autor:innen. Beteiligte Einrichtung: Pediatric Pulmonary Unit and CF Center, The Edmond and Lili Safra Children's Hospital, Chaim Sheba Medical Center, Tel Hashomer, and Faculty of Medic…. Hauptthemen laut MEDLINE: Cystic Fibrosis, Quinolones, Aminophenols, Indoles. Die Arbeit nennt 28 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) modulators revolutionized the care of people with Cystic fibrosis (pwCF) by addressing the underlying genetic defect rather than merely managing symptoms. Elexacaftor/Tezacaftor/Ivacaftor (ETI) has shown significant clinical benefits in pwCF carrying specific CFTR mutations; however, data on its safety and efficacy in young children with CF (ycwCF), aged 2–6 years, remain sparse.

Methods

We conducted a real‐world, retrospective study that included all Israeli ycwCF who were genetically eligible for and treated with ETI. Body mass index (BMI) z‐score, forced expiratory volume in one second (FEV 1 ) percent predicted, rate of pulmonary exacerbations (PEx), sweat conductivity levels, bacterial sputum isolates, clinic visits frequency, and sputum samples collected before and after ETI initiation were evaluated. Additionally, adverse effects were assessed.

Results

Sixteen ycwCF, aged 2–6 years, received ETI therapy for a mean duration of 13 months (range 4–25 months), including three pancreatic‐sufficient patients. Following ETI initiation, significant improvements were observed. BMI z‐scores increased from −0.37 ± 1.32 to −0.01 ± 1.14 ( p = 0.005), and in the subset of patients tested (7/16), FEV 1 improved from 91 ± 12 to 113 ± 18 percent predicted ( p = 0.018). The rate of PEx decreased from 0.7 ± 1.1 to 0.2 ± 0.4 ( p = 0.058) and sweat conductivity levels dropped significantly from 112 ± 38 to 48 ± 30 mmol/L ( p = 0.002). There was a marked reduction in bacterial colonization in sputum: Pseudomonas aeruginosa declined from 9/16 to 2/14 ( p = 0.04), and Staphylococcus aureus from 12/16 to 2/14 ( p = 0.01). Notably, the total number of sputum cultures sent also decreased by 35%, from 116 before ETI to 75 after treatment initiation. This reduction paralleled decreased CF clinic visits, from 7.3 ± 3 per year to 4.7 ± 3 ( p = 0.001). Reported adverse effects were minimal, and no treatment discontinuations were required.

Conclusions

These real‐world findings support the safety and effectiveness of ETI in ycwCF. Robust, long‐term studies involving larger populations are essential to confirm these results.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cystic FibrosisQuinolonesAminophenolsIndolesBenzodioxolesPyrazolesPyridinesPyrrolidinesHumansRetrospective StudiesFemaleChildChild, PreschoolIsraelMaleCystic Fibrosis Transmembrane Conductance RegulatorDrug CombinationsSputumTreatment OutcomeQuinolines

Substanzen

QuinolonesAminophenolsCystic Fibrosis Transmembrane Conductance RegulatorIndolesBenzodioxolesDrug CombinationsPyrazoleselexacaftor, ivacaftor, tezacaftor drug combinationPyridinesPyrrolidines

Autor:innen und Institutionen

  • Pediatric Pulmonary Unit and CF Center, The Edmond and Lili Safra Children's Hospital, Chaim Sheba Medical Center, Tel Hashomer, and Faculty of Medical and Health Sciences, Tel-Aviv University, Tel-Aviv, Israel.
  • Pediatric Pulmonary Unit and CF Center, Hadassah Medical Center and Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.
  • Pulmonary Institute and Graub CF Center, Schneider Children's Medical Center of Israel, Petah Tikva and Faculty of Medical and Health Sciences, Tel-Aviv University, Tel-Aviv, Israel.
  • Pediatric Pulmonary Institute and CF Center, Ruth Rappaport Children's Hospital, Rambam Health Care Campus and Ruth and Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel.

ORCID-Profile: Adi Dagan, Michal Gur, Ronen Bar-Yoseph, Malena Cohen-Cymberknoh

Zitieren

APA

Dagan, A., Hadhud, M., Efrati, O., Cahanovitc, S. S., Prais, D., Gur, M., Bar-Yoseph, R., & Cohen-Cymberknoh, M. (2026). Real‐World Impact of Elexacaftor/Tezacaftor/Ivacaftor in Israeli Children Aged 2–6 With Cystic Fibrosis. Pediatric Pulmonology. https://doi.org/10.1002/ppul.71523

Vancouver

Dagan A, Hadhud M, Efrati O, Cahanovitc SS, Prais D, Gur M, et al. Real‐World Impact of Elexacaftor/Tezacaftor/Ivacaftor in Israeli Children Aged 2–6 With Cystic Fibrosis. Pediatric Pulmonology. 2026. doi:10.1002/ppul.71523

BibTeX
@article{Dagan2026,
  author = {Dagan, Adi and Hadhud, Mohamad and Efrati, Ori and Cahanovitc, Sharon Sarah and Prais, Dario and Gur, Michal and Bar-Yoseph, Ronen and Cohen-Cymberknoh, Malena},
  title = {Real‐World Impact of Elexacaftor/Tezacaftor/Ivacaftor in Israeli Children Aged 2–6 With Cystic Fibrosis},
  journal = {Pediatric Pulmonology},
  year = {2026},
  doi = {10.1002/ppul.71523}
}
Kostenlos starten →